Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2B6 | P20813 | 1/20 | 0.33 |
| ▸ | TENT4A | Q5XG87 | 1/20 | 0.33 |
| ▸ | TENT4B | Q8NDF8 | 1/20 | 0.33 |
| ▸ | FGFR4 | P22455 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21327459 | 0.81 | CYP2B6 (0.35) | CYP2B6TENT4ATENT4BFGFR4 | |
| SCHEMBL29714621 | 0.77 | CYP2B6 (0.33) | CYP2B6TENT4ATENT4BFGFR4 | |
| SCHEMBL21327217 | 0.77 | CYP2B6 (0.33) | CYP2B6TENT4ATENT4BFGFR4 | |
| SCHEMBL29070747 | 0.74 | CYP2B6 (0.35) | CYP2B6TENT4ATENT4B | |
| SCHEMBL21465089 | 0.71 | CYP2B6 (0.35) | CYP2B6TENT4ATENT4B | |
| SCHEMBL28568556 | 0.71 | CYP2B6 (0.35) | CYP2B6TENT4ATENT4B | |
| SCHEMBL22952296 | 0.71 | CYP2B6 (0.35) | CYP2B6TENT4ATENT4B | |
| SCHEMBL21474401 | 0.71 | HTR2A (0.37) | CYP2B6TENT4ATENT4B | |
| SCHEMBL21327168 | 0.69 | CYP2B6 (0.37) | CYP2B6TENT4ATENT4B | |
| SCHEMBL3118756 | 0.68 | REN (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11013726-B2 | Substituted pyridinone-containing trycyclic compounds, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-05-25 | — | — | US | disclosed |
| US-10821103-B2 | Substituted pyridinone-containing trycyclic compounds, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-11-03 | — | — | US | disclosed |
| US-20200261432-A1 | SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-08-20 | — | — | US | disclosed |
| US-20190314347-A1 | SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200261432-A1 | SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME | HAVCR2, HCCS, TYMP | CYP2B6 12/4885TENT4A 251/4885TENT4B 456/4885 |
| US-20190314347-A1 | SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME | HAVCR2, HCCS, TYMP | CYP2B6 12/4885TENT4A 251/4885TENT4B 456/4885 |
| US-11013726-B2 | Substituted pyridinone-containing trycyclic compounds, and methods using same | HAVCR2, HCCS, TYMP | CYP2B6 12/4885TENT4A 251/4885TENT4B 456/4885 |
| US-10821103-B2 | Substituted pyridinone-containing trycyclic compounds, and methods using same | HAVCR2, HCCS, TYMP | CYP2B6 12/4885TENT4A 251/4885TENT4B 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.